Abiraterone and spironolactone in prostate cancer: a combination to avoid

  title={Abiraterone and spironolactone in prostate cancer: a combination to avoid},
  author={B. Dhondt and S. Buelens and J. Van Besien and M. Beysens and E. De Bleser and P. Ost and N. Lumen},
  journal={Acta Clinica Belgica},
  pages={439 - 444}
  • B. Dhondt, S. Buelens, +4 authors N. Lumen
  • Published 2018
  • Medicine
  • Acta Clinica Belgica
  • ABSTRACT Objectives: Disease progression in metastatic castration-resistant prostate cancer (mCRPC) is dependent on androgen signaling. This case describes the complex adaptive androgen signaling mechanisms in mCRPC and illustrates that caution should be exercised when treating these patients with drugs influencing the androgen axis.Methods: Single case report and review of the literature.Results: We report the case of an 86-year-old man with mCRPC, treated with the secondary antihormonal agent… CONTINUE READING
    3 Citations
    Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study
    • 2
    Drug-induced endocrine blood pressure elevation.
    • 5


    Abiraterone and increased survival in metastatic prostate cancer.
    • 3,317
    • PDF
    Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
    • 58
    Abiraterone in metastatic prostate cancer without previous chemotherapy.
    • 1,987
    • PDF
    Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate
    • 9
    Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    • C. Ryan, M. Smith, +9 authors E. Small
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 354